Susan  Morrison net worth and biography

Susan Morrison Biography and Net Worth

Susan Morrison has served as our Chief Administrative Officer since September 2013 and as an Executive Vice President since December 2017, and is responsible for the Company’s investor relations, corporate communications, project management, human resources and facilities functions. From April 2013 until September 2013, she served as our Vice President, Human Resources, Corporate and Investor Relations. Ms. Morrison served as our Director, Corporate and Investor Relations, from January 2009 to March 2013, and was our Director, Corporate Services from November 2007 to December 2008. Prior to joining our Company, Ms. Morrison held various positions in Corporate and Investor Relations at Biosite from August 2003 through November 2007. Ms. Morrison holds a BA in Public Relations from Western Michigan University.

What is Susan Morrison's net worth?

The estimated net worth of Susan Morrison is at least $485,536.72 as of August 28th, 2020. Ms. Morrison owns 13,778 shares of Tandem Diabetes Care stock worth more than $485,537 as of April 26th. This net worth evaluation does not reflect any other investments that Ms. Morrison may own. Additionally, Ms. Morrison receives a salary of $538,210.00 as EVP at Tandem Diabetes Care. Learn More about Susan Morrison's net worth.

How old is Susan Morrison?

Ms. Morrison is currently 45 years old. There are 8 older executives and no younger executives at Tandem Diabetes Care. The oldest executive at Tandem Diabetes Care is Mr. John F. Sheridan, President, CEO & Director, who is 69 years old. Learn More on Susan Morrison's age.

What is Susan Morrison's salary?

As the EVP of Tandem Diabetes Care, Inc., Ms. Morrison earns $538,210.00 per year. There are 5 executives that earn more than Ms. Morrison. The highest earning executive at Tandem Diabetes Care is Mr. John F. Sheridan, President, CEO & Director, who commands a salary of $988,350.00 per year. Learn More on Susan Morrison's salary.

How do I contact Susan Morrison?

The corporate mailing address for Ms. Morrison and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at [email protected]. Learn More on Susan Morrison's contact information.

Has Susan Morrison been buying or selling shares of Tandem Diabetes Care?

Susan Morrison has not been actively trading shares of Tandem Diabetes Care within the last three months. Most recently, Susan Morrison sold 34,624 shares of the business's stock in a transaction on Tuesday, November 16th. The shares were sold at an average price of $142.21, for a transaction totalling $4,923,879.04. Learn More on Susan Morrison's trading history.

Who are Tandem Diabetes Care's active insiders?

Tandem Diabetes Care's insider roster includes David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.

Are insiders buying or selling shares of Tandem Diabetes Care?

In the last twelve months, Tandem Diabetes Care insiders bought shares 6 times. They purchased a total of 27,150 shares worth more than $635,045.95. The most recent insider tranaction occured on November, 27th when Director Dick Allen bought 5,000 shares worth more than $94,800.00. Insiders at Tandem Diabetes Care own 2.5% of the company. Learn More about insider trades at Tandem Diabetes Care.

Information on this page was last updated on 11/27/2023.

Susan Morrison Insider Trading History at Tandem Diabetes Care

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2021Sell34,624$142.21$4,923,879.04View SEC Filing Icon  
11/3/2021Sell5,376$142.00$763,392.00View SEC Filing Icon  
10/13/2021Sell10,048$132.01$1,326,436.48View SEC Filing Icon  
9/1/2020Sell20,000$114.00$2,280,000.0013,778View SEC Filing Icon  
8/28/2020Sell7,522$114.00$857,508.0013,778View SEC Filing Icon  
7/31/2020Sell50,000$108.58$5,429,000.0036,256View SEC Filing Icon  
3/1/2019Sell60,000$67.79$4,067,400.0053,745View SEC Filing Icon  
See Full Table

Susan Morrison Buying and Selling Activity at Tandem Diabetes Care

This chart shows Susan Morrison's buying and selling at Tandem Diabetes Care by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tandem Diabetes Care Company Overview

Tandem Diabetes Care logo
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $35.24
Low: $34.77
High: $35.82

50 Day Range

MA: $30.74
Low: $22.55
High: $35.56

2 Week Range

Now: $35.24
Low: $13.82
High: $40.74

Volume

783,779 shs

Average Volume

1,721,603 shs

Market Capitalization

$2.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12